The fiscal‑year appropriations bill under negotiation includes a provision to streamline Medicare coverage for FDA‑approved multi‑cancer early detection (MCED) tests, making them eligible for reimbursement without waiting on USPSTF endorsement. The measure sets an initial reimbursement benchmark equivalent to multi‑target stool DNA tests and phases in age eligibility, starting in 2029. Separately, congressional agreement preserved NIH funding and other health priorities, signaling bipartisan willingness to accelerate diagnostics coverage and bolster research support.